Zus Health CEO Jonathan Bush on the fu­ture of health records

Last month
Health Tech

Ax­some re­ports Phase 3 de­pres­sion fail for Sunosi

Last month
R&D

Com­pass Ther­a­peu­tics touts tri­al suc­cess in bil­iary tract can­cer, but more da­ta are need­ed

Last month
R&D

Gubra’s Ab­b­Vie-part­nered amylin looks com­pet­i­tive with Zealand’s in ear­ly tri­al

Last month
R&D

Q&A: Demis Has­s­abis talks 'tur­bocharg­ing' Iso­mor­phic with $600M, ex­pand­ing in­to an­ti­bod­ies and the US

Last month
People
AI

Praz­er Ther­a­peu­tics rais­es $20M; Caris­ma lets go of most staff

Last month
News Briefing

Fir­ings sweep across FDA as for­mer lead­ers lament the gut­ting of drug agency

Last month
People
FDA+

Talk­space is us­ing AI to make ther­a­py pod­casts for pa­tients

Last month
AI
Health Tech

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

Last month
Bioregnum
R&D

RNA edit­ing start­up rais­es $155M to bring liv­er and lung dis­ease ther­a­py in­to clin­ic

Last month
Financing
Startups

Lil­ly claims Phase 2 win for siR­NA ap­proach to mixed dys­lipi­demia

Last month
R&D

Sanofi con­tin­ues its bet on R&D by poach­ing GSK’s head of de­vel­op­ment

Last month
People
Pharma

Up­dat­ed: J&J’s third talc bank­rupt­cy bid is stopped by Texas fed­er­al judge 

Last month
Pharma
Law

Fed­er­al judge nix­es FDA's lab-de­vel­oped test rule, says it ex­ceed­ed agen­cy's au­thor­i­ty

Last month
Pharma
Law

DC court sides with HHS in Ver­tex's fer­til­i­ty pro­gram fight

Last month
Pharma
Cell/Gene Tx

What’s next af­ter Marks? At FDA, ques­tions over more top ex­its and fu­ture vi­sion for drug agency

Last month
People
FDA+

Tenaya to lay off about one-third of staff, re­veals heart gene ther­a­py da­ta

Last month
R&D
Cell/Gene Tx

FDA sets new date for opi­oid-fo­cused ad­vi­so­ry meet­ing af­ter ear­li­er de­lay

Last month
FDA+

Vax­cyte's Phase 2 pneu­mo­coc­cal vac­cine da­ta dis­ap­point Wall Street

Last month
R&D

Cor­cept shares soar af­ter Phase 3 win in plat­inum-re­sis­tant ovar­i­an can­cer

Last month
R&D

Mer­ck’s PAH drug cuts risk of se­ri­ous events by 76% in tri­al stopped for ef­fi­ca­cy

Last month
R&D
Pharma

As­traZeneca’s cho­les­terol pill is set for Phase 3, but lags be­hind Mer­ck ri­val

Last month
R&D

Marks’ ex­it at FDA rat­tles an al­ready tee­ter­ing biotech in­dus­try

Last month
R&D
FDA+

Lil­ly's heart dis­ease drug could be dosed as lit­tle as once a year, study shows

Last month
R&D
First page Previous page 20212223242526 Next page Last page
A service from the Financial Times